Oberli, M. A. et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17, 1326–1335 (2017).
Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300–7306 (2015).
Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561–569 (2008).
Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).
Kim, M. et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci. Adv. 7, eabf4398 (2021).
Álvarez-Benedicto, E. et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater. Sci. 10, 549–559 (2022).
Kulkarni, J. A., Witzigmann, D., Leung, J., Tam, Y. Y. C. & Cullis, P. R. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale 11, 21733–21739 (2019).
Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).
Bao, Y. et al. Effect of PEGylation on biodistribution and gene silencing of siRNA/Lipid nanoparticle complexes. Pharm. Res. 30, 342–351 (2013).
Ju, Y. et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano 16, 11769–11780 (2022).
Akinc, A. et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 17, 872–879 (2009).
Urits, I. et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol. Ther. 9, 301–315 (2020).
National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. Moderna COVID-19 vaccine (also known as Spikevax) overview and safety. Centers for Disease Control and Prevention (2022), https://stacks.cdc.gov/view/cdc/115700.
Fabiani, M. et al. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Eurosurveillance 26, 2100420 (2021).
Verma, M. et al. The landscape for lipid-nanoparticle-based genomic medicines. Nat. Rev. drug Discov. 22, 349–350 (2023).
National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases. Possible Side Effects After Getting a COVID-19 Vaccine. Centers for Disease Control and Prevention (2023), https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html.
Turvey, S. E. & Broide, D. H. Innate immunity. J. Allergy Clin. Immunol. 125, S24–S32 (2010).
Nathan, C. Points of control in inflammation. Nature 420, 846–852 (2002).
Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).
Newton, K. & Dixit, V. M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol 4, 3 (2012).
Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343–353 (2015).
Chen, L. et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9, 7204–7218 (2017).
Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6 signaling in clinic. Immunity 50, 1007–1023 (2019).
Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375–386 (2005).
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K. & Oliveira, M. J. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front. Immunol. 9, 847 (2018).
Müller, U. et al. Functional role of Type I and Type II interferons in antiviral defense. Science 264, 1918–1921 (1994).
McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87–103 (2015).
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36–49 (2014).
Perkins, D. J. & Vogel, S. N. Space and time: new considerations about the relationship between Toll-like receptors (TLRs) and type I interferons (IFNs). Cytokine 74, 171–174 (2015).
Garcia, M., Meurs, E. & Esteban, M. The dsRNA protein kinase PKR: virus and cell control. Biochimie 89, 799–811 (2007).
Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C. & Fearon, D. T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348–350 (1996).
Kabelitz, D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 19, 39–45 (2007).
Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987–995 (2004).
Bettelli, E., Oukka, M. & Kuchroo, V. K. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345–350 (2007).
LaRosa, D. F. et al. T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc. Natl Acad. Sci. 105, 3855–3860 (2008).
Li, B., Jones, L. L. & Geiger, T. L. IL-6 promotes T cell proliferation and expansion under inflammatory conditions in association with low-level RORγt expression. J. Immunol. 201, 2934–2946 (2018).
Korn, T. & Hiltensperger, M. Role of IL-6 in the commitment of T cell subsets. Cytokine 146, 155654 (2021).
Karikó, K., Ni, H., Capodici, J., Lamphier, M. & Weissman, D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279, 12542–12550 (2004).
Kokkinopoulos, I., Jordan, W. & Ritter, M. Toll-like receptor mRNA expression patterns in human dendritic cells and monocytes. Mol. Immunol. 42, 957–968 (2005).
Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008).
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543–555 (2022).
Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e2877 (2021).
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).
Risma, K. A. et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J. Allergy Clin. Immunol. 147, 2075–2082.e2072 (2021).
Verma, A. K., Lavine, K. J. & Lin, C.-Y. Myocarditis after Covid-19 mRNA vaccination. N. Engl. J. Med. 385, 1332–1334 (2021).
Parums, D. V. Editorial: SARS-CoV-2 mRNA vaccines and the possible mechanism of vaccine-induced immune thrombotic thrombocytopenia (VITT). Med. Sci. Monit. 27, e932899 (2021).
Nishimura, N. et al. IgA vasculitis following COVID-19 vaccination. Mod. Rheumatol. Case Rep. 7, 122–126 (2023).
Flemming, A. mRNA vaccine shows promise in autoimmunity. Nat. Rev. Immunol. 21, 72–72 (2021).
Chen, Y. et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 165, 386–401 (2022).
Laisuan, W. COVID-19 vaccine anaphylaxis: current evidence and future approaches. Front. Allergy 2, 801322 (2021).
Hung, S. I., Preclaro, I. A. C., Chung, W. H. & Wang, C. W. Immediate hypersensitivity reactions induced by COVID-19 vaccines: current trends, potential mechanisms and prevention strategies. Biomedicines 10, 1260 (2022).
Nilsson, L., Csuth, Á., Storsaeter, J., Garvey, L. H. & Jenmalm, M. C. Vaccine allergy: evidence to consider for COVID-19 vaccines. Curr. Opin. Allergy Clin. Immunol. 21, 401–409 (2021).
Klimek, L. et al. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy 76, 3307–3313 (2021).
Sellaturay, P., Nasser, S., Islam, S., Gurugama, P. & Ewan, P. W. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin. Exp. Allergy 51, 861–863 (2021).
Gill, K. K., Kaddoumi, A. & Nazzal, S. PEG–lipid micelles as drug carriers: physiochemical attributes, formulation principles and biological implication. J. Drug Target. 23, 222–231 (2015).
D’souza, A. A. & Shegokar, R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications. Expert Opin. Drug Deliv. 13, 1257–1275 (2016).
Ibrahim, M. et al. Polyethylene glycol (PEG): the nature, immunogenicity, and role in the hypersensitivity of PEGylated products. J. Control Release 351, 215–230 (2022).
Mohamed, M. et al. PEGylated liposomes: immunological responses. Sci. Technol. Adv. Mater. 20, 710–724 (2019).
Yang, Q. et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88, 11804–11812 (2016).
Szebeni, J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol. Immunol. 61, 163–173 (2014).
Koide, H. et al. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm. 392, 218–223 (2010).
Ishida, T., Wang, X., Shimizu, T., Nawata, K. & Kiwada, H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 122, 349–355 (2007).
Szebeni, J. et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Circ. Physiol. 290, H1050–H1058 (2006).
Guimarães, L. E., Baker, B., Perricone, C. & Shoenfeld, Y. Vaccines, adjuvants and autoimmunity. Pharm. Res. 100, 190–209 (2015).
Toussirot, É. & Bereau, M. Vaccination and induction of autoimmune diseases. Inflamm. Allergy Drug Targets 14, 94–98 (2015).
Wraith, D. C., Goldman, M. & Lambert, P. H. Vaccination and autoimmune disease: what is the evidence. Lancet 362, 1659–1666 (2003).
Banchereau, J. & Pascual, V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383–392 (2006).
Barrat, F. J. et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131–1139 (2005).
Lövgren, T., Eloranta, M. L., Båve, U., Alm, G. V. & Rönnblom, L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 50, 1861–1872 (2004).
Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823–835 (2006).
Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171–1177 (2005).
Crow, M. K., Olferiev, M. & Kirou, K. A. Type I interferons in autoimmune disease. Annu. Rev. Pathol. 14, 369–393 (2019).
Chen, S. et al. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J. Control. Release 235, 236–244 (2016).
Kimura, N. et al. Development of the iLiNP device: fine tuning the lipid nanoparticle size within 10 nm for drug delivery. ACS Omega 3, 5044–5051 (2018).
Hassett, K. J. et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Control. Release 335, 237–246 (2021).
Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).
LoPresti, S. T., Arral, M. L., Chaudhary, N. & Whitehead, K. A. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J. Control. Release 345, 819–831 (2022).
Bevers, S. et al. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells. Mol. Ther. 30, 3078–3094 (2022).
Suzuki, T. et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. Int. J. Pharm. 588, 119792 (2020).
Nakamura, T. et al. The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution. Mol. Pharm. 17, 944–953 (2020).
Thomas, S. N., Rohner, N. A. & Edwards, E. E. Implications of lymphatic transport to lymph nodes in immunity and immunotherapy. Annu. Rev. Biomed. Eng. 18, 207–233 (2016).
Vangasseri, D. P. et al. Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol. 23, 385–395 (2006).
Nakanishi, T. et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem. Biophys. Res. Commun. 240, 793–797 (1997).
Nakanishi, T. et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J. Control. Release 61, 233–240 (1999).
Hilgers, L. A. & Snippe, H. DDA as an immunological adjuvant. Res. Immunol. 143, 494–503 (1992).
Hwang, T. L., Aljuffali, I. A., Lin, C. F., Chang, Y. T. & Fang, J. Y. Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles. Int. J. Nanomed. 10, 371–385 (2015).
Lappalainen, K., Jääskeläinen, I., Syrjänen, K., Urtti, A. & Syrjänen, S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm. Res. 11, 1127–1131 (1994).
Wan, C., Allen, T. M. & Cullis, P. R. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 4, 74–83 (2014).
Semple, S. C. et al. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta 1510, 152–166 (2001).
Wilson, S. C. et al. Real time measurement of PEG shedding from lipid nanoparticles in serum via NMR spectroscopy. Mol. Pharm. 12, 386–392 (2015).
Miteva, M. et al. Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers. Biomaterials 38, 97–107 (2015).
Mehvar, R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharm. Sci. 3, 125–136 (2000).
Jiao, J. et al. The contribution of PEG molecular weights in PEGylated emulsions to the various phases in the accelerated blood clearance (ABC) phenomenon in rats. AAPS PharmSciTech. 21, 300 (2020).
Xu, H., Wang, K. Q., Deng, Y. H. & Chen, D. W. Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes. Biomaterials 31, 4757–4763 (2010).
Son, K. et al. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J. Control. Release 322, 209–216 (2020).
Hu, Y., Hou, Y., Wang, H. & Lu, H. Polysarcosine as an alternative to PEG for therapeutic protein conjugation. Bioconjug. Chem. 29, 2232–2238 (2018).
Miao, L., Zhang, Y. & Huang, L. mRNA vaccine for cancer immunotherapy. Mol. Cancer 20, 41 (2021).
Guevara, M. L., Persano, F. & Persano, S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front. Chem. 8, 589959 (2020).
Shimosakai, R., Khalil, I. A., Kimura, S. & Harashima, H. mRNA-loaded lipid nanoparticles targeting immune cells in the spleen for use as cancer vaccines. Pharmaceuticals 15, 1017 (2022).
AWATE, S., Babiuk, L. & Mutwiri, G. Mechanisms of action of adjuvants. Front. Immunol 4, 114 (2013).
Brito, L. A., Malyala, P. & O’Hagan, D. T. Vaccine adjuvant formulations: a pharmaceutical perspective. Semin. Immunol. 25, 130–145 (2013).
Tom, J. K. et al. Applications of immunomodulatory immune synergies to adjuvant discovery and vaccine development. Trends Biotechnol. 37, 373–388 (2019).
Lee, K. et al. Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy. Biomater. Sci. 8, 1101–1105 (2020).
Luan, N., Cao, H., Wang, Y., Lin, K. & Liu, C. Ionizable lipid nanoparticles enhanced the synergistic adjuvant effect of CpG ODNs and QS21 in a varicella zoster virus glycoprotein E subunit vaccine. Pharmaceutics 14, 973 (2022).
Zhu, D. & Tuo, W. QS-21: a potent vaccine adjuvant. Nat. Prod. Chem. Res. 3, e113 (2016).
Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).
Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA vaccines. Vaccines 9, 65 (2021).
Zhang, Y. et al. STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2. Nano Lett. 23, 2593–2600 (2023).
Ripoll, M. et al. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates. Biomaterials 286, 121570 (2022).
Ruiz, María Esperanza, and Sebastián Scioli Montoto. et al. Routes of drug administration. ADME Processes in Pharmaceutical Sciences: Dosage, Design, and Pharmacotherapy Success, 97–133 (2018).
Francia, V., Schiffelers, R. M., Cullis, P. R. & Witzigmann, D. The biomolecular corona of lipid nanoparticles for gene therapy. Bioconjug. Chem. 31, 2046–2059 (2020).
Van der Jeught, K. et al. Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety. ACS Nano 12, 9815–9829 (2018).
Anderluzzi, G. et al. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency. J. Control. Release 342, 388–399 (2022).
Schnyder, J. L. et al. Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: a systematic review. Travel Med. Infect. Dis. 41, 102007 (2021).
Van Hoecke, L. et al. The opposing effect of type I IFN on the T cell response by non-modified mRNA-lipoplex vaccines is determined by the route of administration. Mol. Ther. Nucleic Acids 22, 373–381 (2020).
Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. 118, e2109256118 (2021).
Zuckerman, J. N. The importance of injecting vaccines into muscle. Different patients need different needle sizes. BMJ 321, 1237–1238 (2000).
Intapiboon, P. et al. Immunogenicity and safety of an intradermal BNT162b2 mRNA vaccine booster after two doses of inactivated SARS-CoV-2 vaccine in healthy population. Vaccines 9, 1375 (2021).
Hunter, J. Intramuscular injection techniques. Nurs. Stand. 22, 35 (2008).
Leveque, D. Subcutaneous administration of anticancer agents. Anticancer Res. 34, 1579–1586 (2014).
Oussoren, C. & Storm, G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 50, 143–156 (2001).
Romani, N. et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr. Top. Microbiol. Immunol. 351, 113–138 (2012).
Kis, E. E., Winter, G. & Myschik, J. Devices for intradermal vaccination. Vaccine 30, 523–538 (2012).
Kim, Y.-C., Jarrahian, C., Zehrung, D., Mitragotri, S. & Prausnitz, M. R. Delivery systems for intradermal vaccination. Intradermal Immun. 351, 77–112 (2012).
Fabrizi, F., Dixit, V., Magnini, M., Elli, A. & Martin, P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharm. Ther. 24, 497–506 (2006).
Schnyder, J. L. et al. Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination – A systematic review and meta-analysis. Travel Med. Infect. Dis. 37, 101868 (2020).
Jung, G. S. & Kim, H. S. A novel technique to reduce pain from intradermal injection of botulinum toxin type A. Plast. Reconstr. Surg. Glob. Open 9, e3417 (2021).
Ipp, M. M. et al. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics 83, 679–682 (1989).
Gallorini, S., O’Hagan, D. T. & Baudner, B. C. In Mucosal Delivery of Biopharmaceuticals: Biology, Challenges and Strategies (eds José das Neves & Bruno Sarmento) 3–33 (Springer, 2014).
Tang, D. C. & Nguyen, H. H. The Yin-Yang arms of vaccines: disease-fighting power versus tissue-destructive inflammation. Expert Rev. Vaccines 13, 417–427 (2014).
Broos, K. et al. Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of Type I interferon. Mol. Ther. Nucleic Acids 5, e326 (2016).
Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523 (2022).
Medzhitov, R. & Janeway, C. Jr Innate immune recognition: mechanisms and pathways. Immunol. Rev. 173, 89–97 (2000).
O’Neill, L. A. J., Golenbock, D. & Bowie, A. G. The history of Toll-like receptors — redefining innate immunity. Nat. Rev. Immunol. 13, 453–460 (2013).
Kopp, E. B. & Medzhitov, R. The Toll-receptor family and control of innate immunity. Curr. Opin. Immunol. 11, 13–18 (1999).
Clement, M. et al. IFITM3 restricts virus-induced inflammatory cytokine production by limiting Nogo-B mediated TLR responses. Nat. Commun. 13, 5294 (2022).
Xu, S. et al. Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps–SHP-2 pathway. Nat. Immunol. 13, 551–559 (2012).
Zheng, D. et al. Epithelial Nlrp10 inflammasome mediates protection against intestinal autoinflammation. Nat. Immunol. 24, 585–594 (2023).
Kagan, J. C. Excess lipids on endosomes dictate NLRP3 localization and inflammasome activation. Nat. Immunol. 24, 3–4 (2023).
Karmacharya, P., Patil, B. R. & Kim, J. O. Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy. J. Pharm. Investig. 52, 415–426 (2022).